IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Segmentation by Drug Class: TNF Inhibitors, Aminosalicylates, Integrin Antagonists, and Corticosteroids; Disease Indication: Ulcerative Colitis and Crohn s Disease; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies, and Forecast, 2019-2027
Sr. No. Chapter 1 Chapter 2 Chapter 3 Chapter 4 Chapter 5 Chapter 6 Chapter 7 Chapter 8 Chapter 9 Chapter 10 Chapter 11 Chapter 12 Chapter 13 Chapter 14 Content Preface Assumptions and Research Methodology Market Overview Market Dynamics Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecasts, By Software Type Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis, by Modality Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis, by Application Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis, by End-user Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast by Region Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast Competition Landscape
Inflammatory bowel disease is a group of medical conditions that causes chronic inflammation in the digestive tract. Inflammatory bowel disease is an umbrella term that comprises two principal disorders: ulcerative colitis and Crohn s disease. Ulcerative colitis is a long-term medical indication that causes inflammation and sores in the inner lining of the colon and rectum. Crohn s disease is part of inflammatory bowel disease that causes inflammation to any part of the gastrointestinal tract, right from mouth to small intestine and anus.
The global IBD (ulcerative colitis and Crohn s disease) treatment market is projected to expand at a ~6% CAGR during the forecast period. Growth of the global IBD treatment market can be attributed to rise in the prevalence of inflammatory bowel diseases across the world, development of novel drugs, novel pipeline drugs, and increase in access to the treatment of IBD. The availability and launch of biosimilar drugs for the treatment of IBD and rise in the adoption of biologic drugs are the other factors fueling the growth of the global IBD treatment market. Rise in investments in building a robust pipeline for IBD and increase in lifestylerelated risk factors are likely to boost the growth of the global IBD treatment market.
The exact cause of inflammatory bowel disease is not known; however, researchers consider the combination of several factors such as autoimmune diseases, genetic factors, unhealthy lifestyles, smoking, and environment that lead to the development of symptoms of inflammatory bowel disease. The global IBD (ulcerative colitis and Crohn s disease) treatment market is consolidated in terms of number of players. A small number of players account for a majority share of the global market. Key players operating in the global IBD treatment market include Valeant Pharmaceuticals International, Inc., Allergan plc, Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Takeda Pharmaceutical Company Limited., AbbVie, Inc., Novartis AG, UCB, Inc., and Biogen, Inc.
To know more about us, please visit our website www.transparencymarketresearch.com For sales queries or new topics email us on: sales@transparencymarketresearch.com Thank You